Slide 1: Q3 2022 results
YW) oa =} Ww ro) 1 a N N (2) N roa) Oo
Slide 2: Financial Highlights
Ww ww aon Sy Te aay = ic UO Cc © Cc =
Slide 3: 3Q22 stable revenue base, EBITDA deteriorates on higher R&D costs
3Q22 reports a stable revenue base year-on-year. At the same time, 3Q22 EBITDA deteriorates due to significant increase in R&D costs. EBITDA margin of the branded generics segment remains at the robust level of 47% despite inflation and demanding labour market. Branded generics Innovative products (
Slide 4: Group and Segment P&L Details
Group and Segment P&L Details Branded generics segment Innovation segment Total PLN million 9M22 9M21 9M22 9M21 9M22 9M21 Revenues from sales of medicines 117,8 129,5 0,0 0,0 117,8 129,5 Other revenues 0,5 2,2 0,0 0,0 0,5 2,2 Revenues from grants 0,0 0,0 21,5 13,6 21,5 13,6 Revenues from sales of li
Slide 5: Balance sheet
Balance sheet PLN mln 2022-09-30 2021-12-31 ASSETS 640,8 707,1 Non-current assets 406,5 428,4 A. In 9M22 the Company maintains stable levels of CAPEX Property, plant and equipment A 298,1 303,7 hence tangible assets record similar levels of nearly Right-of-use assets A 34,8 25,5 Intangible assets B
Slide 6: Generics Sales
Generics Sales 6
Slide 7: Poland – average 2022 quarterly sales above 2021; Export stabilized
Poland – average 2022 quarterly sales above 2021 Export – stabilized at the level of >Euro 1 mln per quarter Generics Sales Dynamics – last 5 quarters 30 28.4 25 25.7 26 24.8 20 20.4 15 10 5 4.2 3.4 3.0 2.7 1.6 0 Domestickraj (w mln market zł)in PLN sales eksport Export(w mlninEuro, sales bez "profi
Slide 8: Poland – increased market shares (ATC 3) for all promoted products
Poland – increased market shares (ATC 3) for all promoted products 10.00 20.00 10.00 10.00 9.00 18.00 9.00 9.00 8.00 16.00 8.00 8.00 14.00 7.00 7.00 7.00 12.00 6.00 6.00 6.00 10.00 5.00 5.00 5.00 8.00 4.00 4.00 4.00 6.00 3.00 3.00 3.00 4.00 2.00 2.00 2.00 2.00 1.00 1.00 1.00 0.00 0.00 0.00 Series1 Q
Slide 9: Poland – increased market shares (molecule/INN) for all promoted products
Poland – increased market shares (molecule/INN) for all promoted products 50.00 40.00 35.00 10.00 45.00 9.00 35.00 30.00 40.00 8.00 30.00 35.00 25.00 7.00 30.00 25.00 6.00 20.00 25.00 20.00 5.00 15.00 20.00 4.00 15.00 15.00 10.00 3.00 10.00 10.00 2.00 5.00 5.00 5.00 1.00 0.00 0.00 0.00 0.00 Series1
Slide 10: Poland – increased market shares (ATC 3) for all promoted products
Poland – increased market shares (ATC 3) for all promoted products 6 15.8 15.6 5.5 15.4 5 15.2 15 4.5 14.8 4 14.6 14.4 3.5 14.2 14 3 10 2 9.5 1.8 1.6 9 1.4 8.5 1.2 8 1 7.5 0.8 0.6 7 0.4 6.5 0.2 6 0 10 X'21 XI'21 XII'21 I'22 II'22 III'22 IV'22 V'22 VI'22 VII'22VIII'22 IX'22 X'21 XI'21 XII'21 I'22 II'
Slide 11: New generic product launches expected in 2023-2025 (Poland)
New generic product launches expected in 2023-2025 (Poland) Registered – Therapeutic Pre- R&D/BD In-Registration launch Area Registration preparation Cardiology BD Cardiology R&D Neuropsychiatry BD Neuropsychiatry BD Oncology R&D 11
Slide 12: Innovations
i?) Cc 2 Y © > oO Cc Cc
Slide 13: R&D project status
D project status CLINICAL DEVELOPMENT MOLECULAR TARGET Iocan neseanci PAE CLNICAL DEVELOPMENT pews | math Drug resistant Falkieri Places v) iv) Schizophrenia CPL'36 / Levodopa-induced @ dyskinesia . Diabetes CPL20 saa o cPLtio Solid tumors (bladder, lung, stomach) cPL'116 eS (various indications)
Slide 14: News flow & milestones 2023
News flow & milestones 2023 Q1 Q2 Q3 Q4 FGFR GPR40 PDE10a end of Phase I/Ib (end of Phase II – in (end of Phase II) diabates) JAK/ROCK in IPF - start JAK/ROCK (End of Phase II in RA) GPR40 (diabetes neuropathy) - start 14
Slide 15: <x Za) Oo
<x Za) Oo